$5.4 Million Raised Through New Partnership with Hi-Lex, Co. Ltd.

Evaheart, Inc. (EVI) hereby announces that 585 million yen (approximately $5.4 million) was raised through third-party allocation of new shares from Hi-Lex, Co. Ltd. (Head office: Takarazuka, Japan), on September 26, 2019.

 After incorporation in February 2014, EVI initiated an FDA-approved IDE clinical trial for the EVAHEART LVAS  as a bridge-to-transplantation. In order to expand the indication of use from bridge-to-transplantation (BTT) to destination therapy (DT), EVI has introduced a new generation LVAS, “EVAHEART 2” with a smaller blood pump and novel inflow cannula.  EVI will raise additional funding for a multi-center randomized clinical trial aiming to achieve BTT/DT designations in the US.